+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 5Years - 17Years
All Genders
ID06690398

Study of Lumateperone to Treat Irritability in Children and Teens with Autism Spectrum Disorder Ages 5 to 17

Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03

160

Participants Needed

39

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled study to evaluate the treatment of irritability associated with Autism Spectrum Disorder ASD in pediatric patients aged 5 to 17 years. The diagnosis of ASD is confirmed using established diagnostic criteria and interviews. The study aims to assess the safety and effectiveness of lumateperone in reducing irritability symptoms in this population. Participants are randomly assigned to one of three groups a high dose of lumateperone, a low dose of lumateperone, or a placebo. The study includes a screening period of up to 14 days to confirm eligibility, followed by a 6-week double-blind treatment period during which the study drug or placebo is taken once daily. After treatment, there is a 1-week safety follow-up visit to monitor any effects after stopping the study drug. During the study, participants will attend visits for assessments including symptom rating scales like the Aberrant Behavior Checklist for irritability and Clinical Global Impression-Severity. Safety will be monitored throughout the trial and during follow-up visits. The total participation time covers screening, treatment, and safety monitoring, with specific evaluations at baseline and week 6 to measure changes in irritability.

CONDITIONS

Brief Title

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here